3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Klaria Pharma Holding AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was -35.66%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Klaria Pharma Holding AB's 3-Year ROIIC % or its related term are showing as below:
FRA:6FN's 3-Year ROIIC % is ranked worse than 81.78% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs FRA:6FN: -35.66
Klaria Pharma Holding AB (FRA:6FN) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Klaria Pharma Holding AB 3-Year ROIIC % Related Terms
Klaria Pharma Holding AB 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Klaria Pharma Holding AB's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klaria Pharma Holding AB 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Klaria Pharma Holding AB's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Klaria Pharma Holding AB's 3-Year ROIIC % falls into.
Klaria Pharma Holding AB 3-Year ROIIC % Calculation
Klaria Pharma Holding AB's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -3.076 (Dec. 2025) - -5.043 (Dec. 2022) )
/
( 4.439 (Dec. 2025) - 9.996 (Dec. 2022) )
=
1.967
/
-5.557
=
-35.40%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Klaria Pharma Holding AB (FRA:6FN) has a 3-Year ROIIC % of -35.66 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Klaria Pharma Holding AB and its competitors. According to the industry distribution chart, Klaria Pharma Holding AB ranks #772 out of 944 companies in the Drug Manufacturers industry, placing it in the top 81.8%.
Is Klaria Pharma Holding AB's 3-Year ROIIC % too high?
Klaria Pharma Holding AB's current 3-Year ROIIC % is -35.66. Based on the distribution chart, Klaria Pharma Holding AB ranks #772 out of 944 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Klaria Pharma Holding AB has a GF Score™ of 7/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Klaria Pharma Holding AB's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Klaria Pharma Holding AB ranks #772 out of 944 companies for 3-Year ROIIC %. This places Klaria Pharma Holding AB in the lower half of its industry. The industry median 3-Year ROIIC % is 3.64. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Klaria Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klaria Pharma Holding AB's current 3-Year ROIIC % is -35.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klaria Pharma Holding AB stock overvalued right now?
Based on GuruFocus' analysis, Klaria Pharma Holding AB (FRA:6FN) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.03, compared to a current price of €0.07 — trading 119% above its estimated fair value. The current 3-Year ROIIC % is -35.66. Klaria Pharma Holding AB's overall GF Score™ is 7/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Klaria Pharma Holding AB (FRA:6FN), the current 3-Year ROIIC % is -35.66 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klaria Pharma Holding AB (FRA:6FN) Overvalued in 2026?
Based on GuruFocus' analysis, Klaria Pharma Holding AB stock appears to be overvalued.
The current stock price of €0.07 is trading 119% above its estimated GF Value™ of €0.03.
GuruFocus considers Klaria Pharma Holding AB to be Significantly Overvalued.
Key valuation signals for FRA:6FN:
3-Year ROIIC %: -35.66
GF Value™: €0.03 vs. price of €0.07 (119% above fair value)
No single metric tells the full story. See the FRA:6FN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klaria Pharma Holding AB is a Swedish pharmaceutical company that develops rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Its patented drug delivery platform consists of an alginate-based polymer film that enables the absorption of a product's active substance through the oral mucosa.
7GF Score
Get the complete analysis for FRA:6FN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6FN has been successfully added to your 
